Geoffrey von Maltzahn

Geoffrey von Maltzahn has an extensive work experience in the life sciences industry, focusing on pioneering and developing innovative biotechnologies and therapies. Geoffrey is currently a General Partner at Flagship Pioneering, where they have been since 2009. In 2018, they became the Founding CEO and Chairman of the Board at Tessera Therapeutics, a company that is revolutionizing gene therapy through its gene writing technology. Additionally, they are the Founding CEO and a Board member of Generate Biomedicines since 2017, which utilizes machine learning to generate new drugs on demand. Von Maltzahn is also the Founding CEO, Chief Innovation Officer, and Board Member of Indigo since 2013, a company that improves sustainable agriculture through natural microbiology and digital technologies. Furthermore, they are a Co-Founder and Board Member of Sana Biotechnology and Cobalt Biomedicine since 2018 and 2016 respectively. Sana Biotechnology focuses on creating and delivering engineered cells as medicine, while Cobalt Biomedicine specializes in developing therapeutics with the ability to deliver biological payloads with high cell specificity. Additionally, von Maltzahn is the Founding CEO and Board Member of Kaleido Biosciences since 2015, a healthcare company focused on leveraging the potential of the microbiome to treat disease. Prior to these roles, they co-founded Seres Therapeutics in 2010, which develops microbiome therapeutics to treat dysbiotic microbiomes, and Axcella Health in 2009, a company focused on reprogramming metabolic dysregulation. Lastly, they co-founded Sienna Biopharmaceuticals in 2009, a clinical-stage biopharmaceutical company specializing in dermatology and aesthetics products.

Geoffrey von Maltzahn completed their education in a consistent field. Geoffrey began their academic journey at the Massachusetts Institute of Technology in 1999, where they received their Bachelor of Science (SB) degree in Chemical Engineering in 2003. Following this, they pursued a Master of Science (MS) degree in Bioengineering at the University of California, San Diego from 2003 to 2005. Finally, Geoffrey von Maltzahn returned to the Massachusetts Institute of Technology and earned a Doctor of Philosophy (PhD) degree in Biomedical Engineering and Medical Physics between 2005 and 2010.